The 427-kDa protein dystrophin is expressed in striated muscle where it physically links the interior of muscle fibers to the extracellular matrix. A range of mutations in the DMD gene encoding dystrophin lead to a severe muscular dystrophy known as Duchenne (DMD) or a typically milder form known as Becker (BMD). Patients with nonsense mutations in dystrophin are specifically targeted by stop codon read-through drugs, whereas out-of-frame deletions and insertions are targeted by exon-skipping therapies. Both treatment strategies are currently in clinical trials. Dystrophin missense mutations, however, cause a wide range of phenotypic severity in patients. The molecular and cellular consequences of such mutations are not well understood, and there are no therapies specifically targeting this genotype. Here, we have modeled two representative missense mutations, L54R and L172H, causing DMD and BMD, respectively, in full-length dystrophin. In vitro, the mutation associated with the mild phenotype (L172H) caused a minor decrease in tertiary stability, whereas the L54R mutation associated with a severe phenotype had a more dramatic effect. When stably expressed in mammalian muscle cells, the mutations caused steadystate decreases in dystrophin protein levels inversely proportional to the tertiary stability and directly caused by proteasomal degradation. Both proteasome inhibitors and heat shock activators were able to increase mutant dystrophin to WT levels, establishing the new cell lines as a platform to screen for potential therapeutics personalized to patients with destabilized dystrophin.
I
n striated muscle cells, the contraction of sarcomeres is coupled to the sarcolemma through the costamere protein network (1) . One substructure of the costamere, known as the dystrophinglycoprotein complex (DGC), physically links the cytoskeleton to the extracellular matrix, contributing to myofiber integrity during contraction and relaxation (2) . One of the key components of the DGC, dystrophin, is a 427-kDa structural protein composed of an N-terminal actin binding domain (ABD1), a central rod region made of 24 spectrin-like repeats that contain binding domains for several proteins (3-6), a cysteine-rich (CR) globular domain, and an intrinsically disordered C-terminal tail (CT) (7) . Dystrophin is encoded by the DMD gene, which is located on the X chromosome and spans over 2.4 Mb of DNA, making it the largest in the human genome (8) .
Males who harbor a disease-causing mutation in their single copy of the DMD gene develop a muscular dystrophy either with severe symptoms known as Duchenne (DMD) or typically milder symptoms referred to as Becker (BMD) (9), occurring with an incidence of ∼1 in 4,000 live male births (10) . Muscle degeneration is progressive and boys lose ambulation in their teenage years. Death occurs in the second or third decade of life, commonly due to cardiac or respiratory failure (11) . The types of mutations causing DMD and BMD include insertions, deletions, point mutations, and splice site mutations (12) . A recent collaborative data bank has calculated that patients with nonsense mutations account for ∼10% of dystrophinopathies (13) , all of whom are the target population for stop codon read-through therapies (14) . Patients with small insertions or deletions (indels) represent ∼7% of the total DMD/ BMD population (13) . When indel mutations cause a frameshift, they can specifically be targeted by current exon-skipping strategies (15) . Patients with missense mutations account for only a small percentage of dystrophinopathies (<1%) (13) , yet they represent an orphaned subpopulation with an undetermined pathomechanism and no current personalized therapies.
The first missense mutation reported to cause DMD was L54R in ABD1 of an 8-y-old patient (16) . Another group later reported L172H, a missense mutation in a structurally analogous location of ABD1 (17) , yet this patient presented with mild symptoms at 42 years of age. We first hypothesized that differential effects on actin-binding affinity could account for differences in disease severity between L54R and L172H. However, biochemical assays reported only nominal effects of six different missense mutations, including L54R and L172H, on actin-binding affinity (18) . In vitro biophysical analyses of the full-length proteins instead revealed that each of the mutations rendered dystrophin more insoluble and less stable during thermal denaturation. Missense mutations analyzed in purified ABD1 fragments also exhibited significant aggregation as assessed by thioflavin T fluorescence, Congo red staining, and electron microscopy (19) .
Although previous research indicates that missense mutations in dystrophin ABD1 cause protein instability and aggregation, no in vitro measurements were able to distinguish between missense mutations that cause severe DMD versus those that cause mild BMD symptoms. There is also currently no understanding of the in vivo cellular consequences of dystrophin instability. If such protein instability does indeed cause protein aggregation in the cell, therapeutic methods may aim at removal or resolubilization Significance Duchenne and Becker muscular dystrophies occur at a frequency of 1:4,000 live male births. Patients experience progressive muscle weakness and often succumb to cardiac or respiratory failure. Many laboratories are investigating potential treatments, including several therapies that target subsets of patients with certain types of mutations. Yet there are currently no treatments specific to patients with missense mutations in the affected protein, dystrophin. Here, we have shown missense mutant dystrophin is degraded by the cell, which can be prevented by several small molecules targeting the cellular degradation machinery. In addition to determining disease mechanism, this work has generated new cell-based models that may aid in the discovery of personalized medicines for dystrophinopathy patients afflicted with missense mutations.
of aggregates akin to treatments for polyglutamine diseases or protein aggregate myopathies (20, 21) . If, however, the unstable dystrophin protein is degraded, then more effective disease treatments may instead focus on stabilizing the mutant protein. Here, we use differential scanning fluorimetry (DSF) to assess the in vitro tertiary structure of L54R and L172H mutant dystrophins, and found that the more severe mutation (L54R) caused greater tertiary instability. Additionally, we generated stable myoblast lines expressing L54R and L172H dystrophin, which revealed that the mutant proteins are degraded by the proteasome to a degree that is inversely proportional to their in vitro stabilities. Flow cytometry used to detect dystrophin showed several small molecules capable of increasing the mutant protein levels, supporting the cell lines' potential for future highthroughput screens for dystrophin stabilizers.
Results

L54R and L172H Cause Different Degrees of Protein Instability in
Vitro. We expressed and purified full-length WT, L54R, and L172H dystrophins (Fig. 1A) using the previously established baculovirus system and FLAG-affinity chromatography (22) . As an additional control, we also expressed and purified full-length dystrophin with the non-disease-causing amino acid substitution I232M (Fig. 1A) , which has been reported by several independent submissions to the SNP database (rs145668843). To determine the stability of the tertiary protein structures, each purified protein was measured by DSF over a temperature gradient from 20 to 90°C (Fig.  1B) . WT dystrophin showed a cooperative unfolding transition (T m = 43.36°C) and the SNP I232M gave a similar melt curve. Mutant dystrophin L172H was slightly left shifted (T m = 42.08°C), indicating a small decrease in protein stability. L54R was more left-shifted (T m = 40.03°C), suggesting either greater thermal instability or the presence of a partially unfolded state of the protein at initiation of the experiment. These DSF results indicate that L54R and L172H cause improper folding of dystrophin, with the mutation leading to severe disease symptoms (L54R) having a greater deleterious effect.
As a sensitive measure of protein aggregation, the hydrodynamic radius of full-length protein was measured by dynamic light scattering (DLS) (Fig. 1 C and D) . DLS analysis of dystrophin isoforms Dp71 and Dp260, and full-length dystrophin yielded z-average sizes that correlated positively with increasing molecular weight as expected (Fig. S1 ). Boiling full-length WT dystrophin protein increased its z-average size by approximately fourfold (Fig. 1C) , demonstrating the large effect of thermal-induced aggregation on z-average size. However, the two missense mutations, L54R and L172H, and the SNP I232M each showed z-average values similar to WT dystrophin, and the polydispersity index was also equivalent across all four proteins (Fig. 1D) . Together, the DSF and DLS data indicate that the DMD and BMD missense mutations cause measurable thermal instability, but do not cause the large-order aggregation more typical of protein aggregation diseases.
L54R and L172H Mutations Lead to Decreased Dystrophin Levels in
Myoblasts. To elucidate the cellular fate of protein instability caused by the L54R and L172H missense mutations, C2C12 myoblast cell lines were generated to stably express full-length WT, L54R, L172H, and I232M dystrophins with amino-terminal GFP tags. The amount of transgene insertion was measured by quantitative PCR (qPCR) of genomic DNA ( Fig. 2A) . The L172H line was found to have approximately twofold higher incorporation of transgene compared with the WT, L54R, and I232M lines. Transcript levels measured by RTqPCR ( Fig. 2B) were elevated in the L172H and I232M lines compared with WT and L54R lines. Despite elevated or similar transcript levels for L172H and L54R, respectively, quantitative Western blot analysis ( Fig. 2C ) revealed graded decreases in the GFP-dystrophin protein levels of L172H and L54R lines compared with WT. Quantification of three separate radioimmunoprecipitation assay (RIPA) lysates revealed that both missense mutations significantly decreased the steady-state level of dystrophin, whereas the SNP I232M increased it significantly (Fig. 2D ). Due to the differences in mRNA expression inherent to stable cell lines ( Fig. 2 A and B) , we normalized the protein levels to their respective transcript level (Fig. 2E) . The steady-state ratio of protein/mRNA revealed that L54R expressed only 13% of WT protein and L172H expressed 46% of WT protein, whereas I232M was comparable to WT. The steady-state levels of WT, severe mutant L54R, mild mutant L172H, and SNP I232M dystrophins in live muscle cells exhibited an inverse relationship with the degree of protein instability measured in vitro (Fig. 1) . The C2C12 myoblast lines were then switched to a low serum media and analyzed after 0, 3, and 7 d to assess whether their differentiation into myotubes had any effect on the steady-state levels of GFP-dystrophin. Western blot analysis of the protein desmin (Fig. 3A) , a marker of myotube differentiation (23) , showed an increase from day 0 to day 7 for each of the cell lines analyzed. For both WT and L54R, there were statistically significant increases in desmin protein from day 0 to day 7 (Fig. 3B) . These results indicate that expression of neither WT dystrophin nor a missense dystrophin had any effect on the ability of the C2C12 cell line to differentiate. GFP-dystrophin protein levels increased in the WT dystrophin line, but the increase was not significant (Fig. 3 A and C) . Most importantly, there was no measureable increase in GFP-dystrophin protein in the L54R line ( Fig. 3 A and C) , indicating that the L54R dystrophin was not stabilized upon differentiation of C2C12 myoblasts into myotubes. Transcript analysis by RT-qPCR confirmed that there was no significant change in GFP-dystrophin transcript levels upon differentiation as expected (Fig. S2 ).
L54R and L172H Mutant Dystrophins Are Degraded by the Proteasome.
The decreased mutant dystrophin levels visible by Western blot analysis (Figs. 2 and 3 ) may have been due to dystrophin aggregates partitioning into RIPA-insoluble compartments of the C2C12 cells. Therefore, the insoluble pellets from the RIPA cell lysates were resolubilized by sonication in 1% SDS and analyzed by Western blot. However, there was no mutant dystrophin detectable in the resolubilized pellets (Fig. 4A) . To determine whether mutant dystrophin was the target of a degradative pathway, the autophagy inhibitor bafilomycin and the proteasome inhibitor MG132 were incubated at increasing concentrations with the L54R cell line and then analyzed for GFP-dystrophin expression by Western blot analysis (Fig. 4B) . In contrast to the positive control p62, no increase in mutant dystrophin protein was observed in cells incubated with increasing concentrations of the autophagy inhibitor bafilomycin (Fig. 4B) . However, there was a clear, dose-dependent increase in L54R dystrophin levels in cells treated with MG132 (Fig. 4B) . These data suggest that the ubiquitin-proteasome system is the major pathway of missense dystrophin degradation. Each of the stable C2C12 cell lines was then treated with increasing concentrations of MG132 to determine the relative degree of proteasomal degradation for each genotype (Fig. 4C) . Because higher doses of MG132 were lethal to the cells, the GFP-dystrophin immunoreactivity at 10 μM MG132 was taken as the maximum protein abundance for each cell line. The ratio of GFP-dystrophin protein at 10 μM MG132 to initial protein at 0 μM MG132 was calculated for each line. L54R dystrophin increased significantly upon proteasomal inhibition compared with WT (Fig. 4D) . These results together indicate that the observed differences in dystrophin protein levels are due to protein degradation.
Previous studies have reported an inverse correlation between dystrophin abundance and disease severity in several mouse models (24) (25) (26) . Here, we have shown a mutant associated with mild disease (L172H) that decreases dystrophin levels approximately by one-half and a mutant associated with severe disease (L54R) that decreases dystrophin to 10% of WT levels in our myoblast model. We therefore hypothesized that abundance of dystrophin protein might correlate with disease severity and that increasing mutant dystrophin levels could ameliorate disease symptoms. Our novel cell lines were administered several compounds to identify small molecules that had a dose-dependent effect on missense dystrophin steady-state levels. First, we screened several osmolytes (Fig. 5A) , which are thought to populate the interior of the cell at high concentrations and therefore enhance thermodynamic stability of proteins (27, 28) . The osmolyte trehalose is commonly synthesized by bacteria and yeast under thermodynamic stress (29, 30) , whereas trimethylamine N-oxide (TMAO) is thought to stabilize proteins against the osmotic pressure in salt water animals (31). However, neither TMAO nor trehalose induced measurable increases in L54R-dystrophin when incubated with concentrations up to 200 mM, and cells did not survive higher concentrations of 400 mM TMAO or 500 mM trehalose. The kidney osmolyte betaine (32) caused an increase in GFP-dystrophin in the mutant L54R line, but only at a concentration (400 mM) that argues against its potential as a therapeutic. Although the heat shock system is directly linked to the proteasome degradation pathway (33), we found that there was no global up-regulation in heat shock proteins associated with expression of mutant GFP-dystrophins alone (Fig. S3) . Therefore, exogenous up-regulation of the heat shock system has the potential to affect missense dystrophin abundance. The smallmolecule celastrol activates the conserved heat shock factor 1 (HSF1) (34, 35) , but caused no increase in mutant L54R GFPdystrophin levels at concentrations up to 1 μM. The compound BGP-15 specifically induces one of the heat shock proteins, HSP72, and has been shown to alleviate symptoms in models of diabetes and muscular dystrophy (36, 37) . However, we saw no direct molecular effect on L54R GFP-dystrophin levels at tolerated concentrations up to 50 μM. Finally, we tested gedunin, which binds to and inhibits Hsp90, thereby releasing bound HSF1 for transcriptional activity (38, 39) . Increasing L54R GFP-dystrophin was observed in cells treated with 10-80 μM gedunin, suggesting that pharmacologic activation of the heat shock system can facilitate stabilization of mutant dystrophin.
Given that the general proteasome inhibitor MG132 effectively increased mutant GFP-dystrophin levels (Fig. 4) , we evaluated several additional proteasome inhibitors (Fig. 5A) . The MG132 derivative, MG262, gave similar results at even lower concentrations than MG132. Bortezomib is a member of the boronic acid class of proteasome inhibitors (40) and was recently demonstrated to increase levels of missense mutated dysferlin in vivo (41) . Bortezomib had a strong concentration-dependent effect on increasing L54R GFP-dystrophin protein levels. Epoxomycin is in the epoxyketone class of proteasome inhibitors (40) and also had a robust concentration-dependent effect on mutant GFP-dystrophin levels. We further investigated the effects of three of the positive hits: gedunin, bortezomib, and epoxomicin. Both L54R and L172H myoblast lines were treated in parallel with submaximal doses of each small molecule (Fig. 5B) . Western blot analysis of the GFP-dystrophin protein demonstrated marked increases in the L54R line for all three small molecules. The L172H mutant dystrophin was also increased when treated with either bortezomib or epoxomicin. Western blot analysis of ubiquitin (Fig. 5B, Bottom) revealed that both proteasome inhibitors caused a large increase in ubiquitination across the proteome. The heat shock activator gedunin had a similar effect on ubiquitination in the cell, emphasizing the close connection between the heat shock and the ubiquitin-proteasome pathways. These data also corroborate previous studies that have found Hsp90 inhibition increases ubiquitination (42) . The heat shock system was confirmed to be up-regulated upon treatment with each of the small-molecule compounds (Fig. S4) . Finally, treatment of the L54R and L172H GFP-dystrophin cell lines with submaximal doses of gedunin, bortezomib, or epoxomicin each caused marked increases in the cellular GFP fluorescence measured by flow cytometry (Fig. 5 C and D) . These results both confirm the Western blot results and validate flow cytometry as a high-throughput method to screen the cell lines for stabilizers of misfolded dystrophin.
Discussion
Previous studies have demonstrated that several missense mutations in ABD1 of dystrophin cause protein instability in vitro (18, 19) . Here, we were able to distinguish between a missense mutation associated with DMD (L54R) from one associated with BMD (L172H) by monitoring protein tertiary structure in vitro (Fig. 1B) . Our myoblast cell lines expressing full-length WT and missense dystrophins have revealed that tertiary structure instability leads to a corresponding decrease in the steady-state cellular level of dystrophin (Fig. 2E ), which appears to be directly controlled by proteasomal degradation (Fig. 4B) . The C2C12 myoblast model thereby recapitulates reported symptoms of the modeled patients. Dystrophin Western blot analysis of muscle from the L54R DMD patient revealed a large decrease in full-length dystrophin protein, whereas immunofluorescence analysis showed dystrophin properly localized to the sarcolemma, but at reduced intensity (16) . Similarly, muscle from the L172H BMD patient presented with decreased levels of full-length dystrophin assessed by Western blot and correct localization by immunofluorescence microscopy (17) . Although our data suggest that a reduction in total dystrophin levels caused by proteasomal degradation may contribute to the dystrophic phenotype in patients afflicted with missense mutations, the severe phenotype of L54R in a human patient with residual sarcolemmal localization (16) leaves open the possibility that the mutation also perturbs dystrophin function. In support of this possibility, we previously demonstrated a significant reduction in the actin-binding affinity of mouse dystrophin bearing the L54R mutation (18) .
The absence of large-order structures seen by DLS (Fig. 1D) , the high solubility in cell culture (Fig. 4A) , and the lack of effect of an autophagy inhibitor (Fig. 4B) all indicate that the L54R and L172H missense mutations do not cause dystrophin to form aggregates in the cell. These data differentiate missense mutant dystrophinopathy from the protein aggregate myopathies (PAMs) (21, 43) . In PAM diseases, the causative mutant protein evades degradation, forming fibrils or aggregation conglomerates along with other muscle proteins. Often a gain-of-function, toxic effect is caused by the aggregates, and therefore treatment for these diseases is twofold: removing the aggregate and replacing it with a functional protein. The L54R and L172H mutant dystrophins expressed in myoblasts are degraded by the proteasome, and therefore treatment is potentially onefold: inhibiting degradation of the mutant protein. Our small-molecule screen found several compounds that were able to increase mutant dystrophin levels (Fig. 5A) . The osmolyte betaine stabilized mutant dystrophin at very high concentrations, and the heat shock activator gedunin increased dystrophin protein levels at moderate concentrations. The efficacy of gedunin supports heat shock activators as a class of compounds with potential to treat DMD patients with missense mutations, and a broader screen may identify heat shock activators effective at lower doses.
The most successful class of small molecules for increasing mutant dystrophin levels was proteasome inhibitors. Each of the tested proteasome inhibitors restored mutant dystrophin to WT levels at concentrations less than 10 μM. Several previous studies have tested proteasome inhibition to treat the nonsense mutation mdx mouse model of dystrophinopathy (44) (45) (46) (47) but have reported contradictory results. Although proteasome inhibition by MG132 in the mdx mouse restored the amino-terminal fragment of dystrophin translated up to the premature stop codon (44) , prolonged treatment with MG132 resulted in no improvement of muscle function (46) . It has therefore been hypothesized that proteasome inhibition of nonsense dystrophin may treat some of the symptoms of dystrophinopathy such as decreased DGC expression but does not treat the primary cause of disease (48) . Our data demonstrate that proteasome inhibition restores full-length, missense dystrophin to WT levels. It is possible that the missense dystrophin could be largely functional given that missense mutations in the ABD1 did not dramatically affect actin-binding affinity (18) . Indeed, proteasome inhibition in a missense dysferlin model has been shown to restore functional protein (49) . If restored missense dystrophin proves to be at least partially functional, then proteasome inhibition may be an effective, personalized treatment for the missense subpopulation of dystrophinopathy patients.
Proteasome inhibitors such as bortezomib and epoxomicin derivative carfilzomib are currently being used in the clinic for treatment of multiple myeloma and other cancers (40) . In contrast to the acute treatment regimen necessary to treat cancer patients, further work is needed to determine whether chronic proteasome inhibition could be tolerated by missense mutant dystrophinopathy patients requiring treatment over their lifetimes. For example, up to 30% of even WT proteins are estimated to be degraded by the proteasome due to misfolding (50) so global proteasome inhibition may have adverse consequences. Alternatively, pharmacologic inhibition of the ubiquitination ligases specific to skeletal muscle or even dystrophin could be more effective therapeutics with fewer side effects. Indeed, the cancer biology field, which has been using proteasome inhibitors for treatment of multiple myeloma (51) , has recently begun to target the cancer-specific E3 ligases responsible for ubiquitination of p53 and c-Myc (52) . Although identifying the specific E1-E2-E3 cascade for a given substrate is a difficult task (53, 54) , our stable missense dystrophin cell lines provide a high-throughput screening platform ( Fig. 5 C and D) that could allow for the efficient identification of the enzymes responsible for ubiquitination and subsequent degradation of misfolded dystrophin.
Although missense mutations represent a very small percentage of dystrophinopathy patients, therapies directed at such patients may also be more broadly applicable to any patient with compromised dystrophin stability. BMD is often the result of inframe deletions or insertions, resulting in internally truncated dystrophin protein. In addition to potentially lacking functional domains, internally truncated dystrophin has been shown to be thermally unstable in vitro (55) , and BMD patients often present with a decreased abundance of dystrophin (56) . In addition, small-molecule stabilizers of misfolded dystrophin or targeted E3 ligase inhibition may also be useful adjuvants to other personalized therapies dependent on the functionality of sequencealtered dystrophins such as exon-skipping (15), virus-based gene therapy (57, 58) and stop codon read-through drugs (14) . Therefore, development of any therapy that stabilizes and/or prevents degradation of misfolded dystrophin could potentially benefit the DMD patient community as a whole.
Materials and Methods
Detailed descriptions of cloning, protein expression and purification, DSF, DLS, generation of mammalian cell lines, cell culture and differentiation, qPCR, RT-qPCR, Western blot analysis, solubility assay, small-molecule treatments, flow cytometry, and statistical analysis are provided in SI Materials and Methods.
